Name : Ms. MAUSUMI MITRA (59 /F) Date : 01/04/2024

Address :

Examined by: UHID : AMHL.0002132240

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE AHC No : AMHLAH202092

FEMALE HCK



For corporate health checkup

No specific complaints

PRESENT KNOWN ILLNESS

No history of - Diabetes mellitus,

Dyslipidemia, Thyroid disorder, Heart disease,

Stroke, Asthma

Hypertension Since - 2016; Medication -

regular



NO KNOWN ALLERGY :01/04/2024



Cardiovascular system

- Nil Significant

Respiratory system

- Nil Significant

Gastrointestinal system

Appetite - normal; Dyspepsia - no; Bowel habits - regular; Piles - no; Hernia - no; - H/O Cholelithiasis

Genitourinary system

- Nil Significant

Gynaec history

Last menstrual period - 8 yrs; Menopause - yes;

Since - 8 yrs

Eyes

Vision - normal with glasses

ENT

- Nil Significant

Musculoskeletal system

Spine and joints

Knee (bilateral) - pain

Skin

- Nil Significant



Present medications

- T Stamlo D T Tazloc beta 40 T Ecosprin 75

Past medical history

Do you have any - No

allergies?

Do you have any drug - No

allergies?

Covid 19 - Yes Hospitalization for - No

Covid 19

Malaria - in childhood



Surgical history - Nil

Personal history

Marital status - Single

Diet - Non Vegetarian

Alcohol - does not consume alcohol

Smoking - No
Chews tobacco - No
Physical activity - Mild

Family history

Father - has expired

Mother - alive Brothers - 1

Diabetes - father,mother

Hypertension - father,mother

Coronary artery - father,mother

disease

Cancer - father
Type - Lymphoma

Name : Ms. MAUSUMI MITRA (59 /F) UHID : AMHL.0002132240 Date : 01/04/2024

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH202092

PHYSICAL EXAMINATION



General

Build - over weight

 Height
 - 148

 Weight
 - 54.9

 BMI
 - 25.06

 Pallor
 - No

 Oedema
 - no



Cardiovascular system

Heart rate (Per minute) - 78

Rhythm - Regular

- B.P. Sitting

Systolic(mm of Hg) - 138

Diastolic(mm of Hg) - 72

Heart sounds - S1S2+

Respiratory system

Breath sounds - Normal vesicular breath

sounds



Organomegaly - No Tenderness - No



- No significant finding

Opthalmology consultation

Opthalmology findings - PGVA:RE:6/9 LE:6/9

BCVA:RE:N6 LE:N6

OCULAR MOVEMENT:WNL

ANT.SEG:EARLY CHANGES

ADVICE:*To continue present glass Rx*Detail dilated Funduscopy*Review

after 1yr/SOS

Printed By: Benazir Begaum

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No: AMHLAH202092

	GRAM PI			_	Casts:	Not Fou	ına		
Test Name	Result		Level	Range	Crystals:	Not Fou	ınd		
Hemoglobin	11.8 *	g/dl		12.0-15.0	LIDINE CUCAD DOC	T DDAN	DIAI		
RBC COUNT	4.07	Millic ul	on/	3.8-4.8	URINE SUGAR - POS (QUALITATIVE)	IPKAN	DIAL		
Hematocrit - Hct:	35.3 *	%		36-46	Test Name	Result	Unit	Level	Range
MCV	86.6	fl		83-101	URINE GLUCOSE(POST	Nil			
MCH	29.0	pg		27-32	PRANDIAL)				
MCHC	33.5	%		31.5-34.5	LIDINE CLICAD EACT	INC/OU	A I ITA-	FIVE\	
RDW	14.0	%		11.8-14.0	URINE SUGAR- FAST Test Name	Result		-	Range
WBC Count	8700	/cu n	nm 🗨	4000-10000	URINE	Nil	Oint	20101	rungo
Platelet Count	1.80	lacs/ mm	cu •	1.5-4.0	GLUCOSE(FASTING)				
Neutrophils	63	%		40-80	BLOOD GROUPING A		•		
Lymphocytes	26	%		20-40	Test Name		Unit	Level	Range
Monocytes	08	%		2-10	ABO Group:	Α			
Eosinophils	03	%		01-06	Rh (D) Type:	POSITI	VΕ		
Basophils	00	%		0-0	LIVER FUNCTION TE	ST (PAC	KAGE)	
RBC:	Normoc	ytic No	rmochro	mic cells	Test Name	Result	Unit	Level	Range
Platelets:	Adequa	te on th	ne smea	r	ALT(SGPT) - SERUM	17	U/L		0-35
ERYTHROCYTE SEDIMENTATION	57 *	mm/ hr	1st	0-20	ALBUMIN - SERUM	4.0	g/dL	•	3.5-5.1
RATE (ESR)					ALKALINE PHOSPHATASE -	99 *	U/L		33-98
IRINE ROUTINE AN	ID MICRO	SCOF	Υ		SERUM				
Test Name	Result	Unit	Level	Range					
Volume:	30	mL			AST (SGOT) - SERUM	21	U/L		0-35
Colour:	Pale Str	Pale Straw Slightly Turbid			BILIRUBIN TOTAL - SERUM	0.5	mg/dl		0.3-1.2
Appearance	Slightly					0.0			0.0 1.2
Specific Gravity	1.015				LIPID PROFILE TEST	(DACK)	(CE)		
рН:	8.0				Test Name	Result	-	Level	Range
Albumin:	Not Det	ected			CHOLESTEROL -	138	mg/dl		0-200
Glucose	Not Det	ected			SERUM				
Ketone:	Not Det	ected			CREATININE - SERUI	И			
Bile Pigments	Not Det	ected			Test Name	Result	Unit	Level	Range
RBC	Occasio	na (hpf			CREATININE - SERUM	0.7	mg/dl	_	0.6-1.1
Pus Cells	2-4	/hpf			LIVED EUNOTION TE	OT /DA 0	V A OF		
Epithelial Cells	4-6 /h.p.	f /hpf			LIVER FUNCTION TE Test Name	•		•	Range

Name : Ms. MAUSUMI MITRA (59 /F) UHID : AMHL.0002132240 **Date** : 01/04/2024 Package: MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No: AMHLAH202092 U/L GGTP: GAMMA ng/ml 19 0-38 TOTAL T3: TRI 1.33 0.87-1.78 **GLUTAMYL IODOTHYRONINE -**TRANSPEPTIDASE -SERUM **SERUM** TOTAL T4: 13.74 μg/dL 5.48-14.28 **GLUCOSE - PLASMA (FASTING)** THYROXINE - SERUM **Test Name** Result Unit Level Range LIPID PROFILE TEST (PACKAGE) mg/dL GLUCOSE - PLASMA 92 70-99 (FASTING) **Test Name** Result Unit Level Range TRIGLYCERIDES -96 mg/dL 0-150 GLUCOSE - PLASMA (POST PRANDIAL) **SERUM Test Name** Result Unit Level Range THYROID PROFILE - I(T3,T4 AND TSH) **GLUCOSE - PLASMA** 125 mg/dL 70-140 (POST PRANDIAL) **Test Name** Result Unit Level Range TSH: THYROID μIU/mL 0.38-5.33 4.16 **HBA1C (GLYCOSYLATED** STIMULATING HAEMOGLOBIN)-WHOLE BLOOD HORMONE - SERUM **Test Name** Result Unit Level Range **URIC ACID - SERUM** HBA1C 5.4 % Nondiadetic: 4 (GLYCOSYLATED - 5.6 % **Test Name** Result Unit Level Range HAEMOGLOBIN)-WHO Prediabetics: **URIC ACID - SERUM** 3.9 mg/dL 2.4-5.7 LE BLOOD 5.7 - 6.4% Diabetes LIVER FUNCTION TEST (PACKAGE) >/= 6.5% **Test Name** Result Unit Level Range **ADA** Theraputic goal **BILIRUBIN** 0.1 mg/dL 0.0-0.2 : <7% **CONJUGATED** (DIRECT) - SERUM LIPID PROFILE TEST (PACKAGE) **BUN (BLOOD UREA NITROGEN) Test Name** Result Unit Level Range **Test Name** Result Unit HDI CHOLESTEROL -52 mg/dL 30-70 Level Range **SERUM** mg/dL BUN (BLOOD UREA 16.8 7.0-18.0 NITROGEN) LDL CHOLESTEROL 82 mg/dL 0-100 LIVER FUNCTION TEST (PACKAGE) -SERUM Result Unit **Test Name** Level Range VLDL CHOLESTEROL mg/dL 0-35 A/G - RATIO SERUM (Calculated) 1.3 1.0 - 2.0LIVER FUNCTION TEST (PACKAGE) **BUN/CREATININE RATIO** Result Unit **Test Name** Level Range **Test Name** Result Unit Level Range g/dL PROTEIN TOTAL -7.1 6.4-8.3 **BUN/CREATININE** 22.7 **SERUM RATIO** GLOBULIN: 3.1 g/dL 1.8-3.6 (CALCULATED) -**ECG SERUM** SINUS RHYTHM. THYROID PROFILE - I(T3,T4 AND TSH) RSR PATTERN. **Test Name** Result Unit Level Range

Borderline High/Low

Out of Range

Within Normal Range

Name : Ms. MAUSUMI MITRA (59 /F) UHID ; AMHL.0002132240 Date ; 01/04/2024

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No; AMHLAH202092

ULTRASOUND SCREENING WHOLE ABDOMEN

- * Grade I fatty liver.
- * Cholelithiasis.

[NOTE: At times pelvic structures are not well visualized due to inadequate patient preparation / excess bowel gas shadow. However suggested clinical correlation and other investigations if clinically indicated.]

X-RAY CHEST PA

 * Chest skiagram does not reveal any significant abnormality.

X-RAY MAMMOGRAPHY BILATERAL (MHC)

* Heterogeneously dense bilateral breast which may obscure small masses- BIRADS 0

Bilateral breasts benign calcifications

Advise further evaluation by sonography

BIRADS Category:

- 0. Requires additional evaluation
- 1. Negative
- 2. Benign findings
- 3. Intermediate
- 4. Suspicious malignancy
- 5. Highly suggestive of malignancy
- 6: (Histo-pathologically proven)

---END OF THE REPORT---

Dr. SUDESHNA MALAKAR MD, DNB, MNAMS, FRCR CONSULTANT RADIOLOGIST Reg. No ?" 70658 (WBMC)

INVESTIGATIONS NOT DONE / NOT YET REPORTED / NOT PART OF PACKAGE(LAB,RADIOLOGY & CARDIOLOGY)

Histopathology

PAP SMEAR /CERVICAL SMEAR

CARDIOLOGY

TREADMILL TEST / STRESS TEST

Within Normal Range

Borderline High/Low



Out of Range

Name	: Ms. MAUSUMI MITRA (59 /F)	UHID : AMHL.0002132240	Date	: 01/04/2024
Naille	. IVIS. IVIAUSUIVII IVII I IVA (33/I /	OTTID : AWITIL.UUUZ 13224U	Date	01/04/2024

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No: AMHLAH202092

Printed By: AHC Physician / Consultant Internal Medicine

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases.

Name : Ms. MAUSUMI MITRA (59 /F) UHID ; AMHL.0002132240 Date ; 01/04/2024

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No; AMHLAH202092

AICVD RISK SCORE REPORT

RISK STATUS	YOUR SCORE	ACCEPTABLE SCORE
Moderate Risk	7	7

Your likelihood of developing cardiovascular disease in the next ten years is 1.3 times higher than the people of your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence-based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with **medications** for high blood pressure, diabetes, or dyslipidemia, if advised by your physician.Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.
- · Follow your physician's advice regarding follow up tests, consults and annual health assessment
- It is recommended that you visit your physician every 6 months if you have:
 - Uncontrolled high blood pressure, Diabetes, Dyslipidemia, Coronary heart disease

DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging, treatment or patient education related to lifestyle management is under the physician's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side.
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

The Clinical Al Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515